<DOC>
	<DOCNO>NCT01288157</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics golimumab Chinese male participant .</brief_summary>
	<brief_title>A Study Pharmacokinetics Golimumab Chinese Male Subjects</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( physician subject know assign study medication ) study assess safety , tolerability , immune response , pharmacokinetics ( body drug ) , golimumab ( Simponi ) . The study population consist 24 healthy male participant China . Subjects receive single dose either 50 mg 100 mg golimumab . Subjects study 14 week . Safety assessment perform throughout study include obtain evaluate laboratory test , vital sign ( eg , blood pressure ) , occurrence severity adverse event . A single dose 50 mg 100 mg golimumab subcutaneous injection .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have clinically relevant abnormality nonsmoker agree smoke 10 cigarette 2 cigar per day throughout study . Have history clinically significant , severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Have underlying physical psychological medical condition Be unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>healthy</keyword>
	<keyword>adult</keyword>
	<keyword>Chinese</keyword>
	<keyword>male</keyword>
	<keyword>Simponi</keyword>
	<keyword>CNTO 148</keyword>
</DOC>